Combining obesity medications with structured lifestyle programs delivers the biggest BMI reductions in children and teens, a new network meta-analysis in JAMA Pediatrics finds. Semaglutide plus counseling showed the largest BMI drop, while even basic lifestyle support boosted drug effectiveness. Researchers stress that medications should never be prescribed alone for young patients.
A new network meta-analysis published in JAMA Pediatrics confirms that obesity drugs work significantly better in children and adolescents when paired with structured lifestyle support. Analyzing 42 randomized clinical trials involving nearly 3,900 young people aged 10–19, researchers found that combination approaches consistently outperformed either medication or lifestyle intervention alone across short-term follow-up periods of 6–12 months.
The standout finding? Semaglutide combined with counseling was linked to the greatest BMI reduction of all interventions studied. Even pairing metformin — a more modest drug — with behavioral treatment yielded meaningful BMI drops, while metformin alone showed no significant effect. Notably, structured lifestyle treatment on its own matched or beat several medications used in isolation.
By the Numbers:
Why it matters: With obesity rates rising among youth, these findings send a clear message to prescribers — medications should always be bundled with lifestyle and family-centered support, not handed out in isolation. A personalized, whole-patient approach isn't just best practice; it's what the evidence demands.
